COMMUNICATION:
Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases*

(Received for publication, March 14, 1997, and in revised form, April 9, 1997)

Peter Erhardt Dagger , Kevin J. Tomaselli § and Geoffrey M. Cooper Dagger

From the Dagger  Division of Molecular Genetics, Dana-Farber Cancer Institute and the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 and § IDUN Pharmaceuticals, Inc., La Jolla, California 92037

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Programmed cell death is mediated by members of the interleukin 1-beta convertase family of proteases, which are activated in response to diverse cell death stimuli. However, the key substrates of these proteases that are responsible for apoptotic cell death have not been identified. Here we report that the MDM2 oncoprotein is cleaved by members of the CPP32 subfamily of interleukin 1-beta convertase proteases both in vitro and in vivo, resulting in the disappearance of MDM2 from apoptotic cells. Because MDM2 functions as a negative regulator of the p53 tumor suppressor and because p53 induces apoptosis in response to a variety of stimuli, this cleavage of MDM2 by CPP32-like proteases may result in deregulation of p53 and contribute directly to the process of apoptotic cell death.


INTRODUCTION

Programmed cell death (apoptosis) plays a key role in normal development as well as in the pathogenesis of many diseases (1, 2). Diverse stimuli utilize cell death effectors that are conserved from nematodes to mammals (3-5). The executioner phase of apoptosis is initiated by the interleukin 1-beta convertase (ICE)1 family of proteases, which are homologous to Ced-3, a protease essential for cell death in Caenorhabditis elegans (6). The mammalian ICE (or caspase) family consists of three subfamilies, designated the ICE-like, the Ich1-like, and the CPP32-like subfamilies (7-9), which show distinct substrate specificities and may play different roles in apoptosis. However, the mechanism by which these proteases induce apoptotic cell death is not known. Substrates of ICE family proteases include nuclear lamins, cytoskeletal components, and proteins involved in DNA repair, RNA processing, and signal transduction (7, 10-12). Cleavage of lamin contributes to fragmentation of apoptotic nuclei (13), but the relevance of other known substrates to cell death is unclear.

Here we report that the oncoprotein MDM2 is a substrate of CPP32-like apoptotic proteases. Because MDM2 is a negative regulator of the tumor suppressor p53, which induces both apoptosis and cell cycle arrest (14-16), these results identify MDM2 as a protease substrate that may play a direct role in the cell death program.


EXPERIMENTAL PROCEDURES

Construction of Plasmids

Wild type mouse mdm2 (17) was a generous gift of Donna L. George (Thomas Jefferson University, Philadelphia, PA). Substitution of aspartate 359 with glutamic acid was accomplished by converting the aspartic acid codon GAU to GAA by Altered Sites II in vitro Mutagenesis System (Promega) using a synthetic oligonucleotide. Both WT and D359E mdm2 were HA-tagged by subcloning into pJ3H (18), then into pcDNA3 (InVitrogen) plasmids.

Transfections

COS-7 cells were transiently transfected with the lipofectamine method as suggested by the manufacturer (Life Technologies, Inc.). Briefly, 15 µl of lipofectamine plus 5 µg of plasmids were incubated with the cells for 5 h, then the medium was replaced with DMEM supplemented with 10% calf serum for 24 h.

Immunoblot Analysis

Cell lysates were electrophoresed and immunoblotted as described (19). All primary antibodies were from Santa Cruz Biotechnology, except for anti-PARP (obtained from G. G. Poirier, Laval University, Quebec, Canada); anti-CPP32 (Transduction Laboratories); and anti-HA (Boehringer Mannheim).

Preparation of Cytosols

Cytosols were prepared essentially as described (20). Briefly, cells were washed twice with phosphate-buffered saline and once with an extraction buffer consisting of 50 mM PIPES, pH 7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM dithiothreitol, 20 µM cytochalasin B, and protease inhibitors. Cells were then resuspended in extraction buffer (100 µl/108 cells), incubated on ice for 20 min, and disrupted with a glass Dounce homogenizer. The cell lysate was centrifuged, first at 10,000 × g for 10 min and then at 100,000 g for 90 min at 4 °C. The final supernatant was used as cytosolic extract.

Immunodepletion of Cytosols

Cytosolic extracts were immunoprecipitated twice with either anti-CPP32 or the nonrelated anti-p21 antibody as control. Each immunoprecipitation was carried out with a 1:100 dilution of the primary antibodies for 1 h at 4 °C. The antigen-antibody complexes were collected on protein A Sepharose CL-4B beads (Pharmacia Biotech Inc.) by incubation for 1 h at 4 °C, and the final supernatants were considered as immunodepleted cytosols.

Purification of Proteases

(His)6-tagged human CPP32, Mch2, Mch3, and mouse ICE were expressed in Escherichia coli (21). Enzymes were either purified by Ni2+ affinity chromatography or the soluble fraction of sonicated bacterial lysates were used directly in protease assays. The activity of enzyme preparations was first determined with synthetic peptide substrates, defining 1 unit of enzyme as the amount needed to release 1 µM fluorescent aminomethylcoumarine (AMC)/h using 10 µM DEVD-AMC for CPP32, Mch3, and Mch2 or 10 µM YVAD-AMC for ICE.

In Vitro Cleavage Assay

35S-labeled MDM2 was prepared by in vitro translation using the TNT-linked transcription/translation kit (Promega, Madison, WI) with T7 polymerase and mouse mdm2 cDNA in a Bluescript KS plasmid. In vitro translated 35S-MDM2 (2 µl of 50-µl final volume of the TNT reaction) was incubated without proteases or with 5 µg of cytosolic extracts from control or apoptotic cultures or with purified proteases for 1 h at 30 °C in a 20-µl reaction mixture containing 25 mM Hepes, pH 7.5, 0.1% CHAPS, and 1 mM dithiothreitol.


RESULTS AND DISCUSSION

Degradation of MDM2 in Apoptotic Cells

Recent studies have indicated that the phosphatidylinositol (PI) 3-kinase signaling pathway plays a key role in preventing apoptosis of growth factor dependent cells (22, 23). Expression of dominant negative p53 inhibited apoptosis of PC12 and Rat-1 cells in response to either serum deprivation or PI 3-kinase inhibition, suggesting the involvement of p53 in this pathway of apoptotic cell death.2 We therefore investigated the induction of p53 and p53 target genes following either growth factor deprivation or PI 3-kinase inhibition (Fig. 1). Populations enriched in apoptotic cells were obtained by collecting cells that had detached from the culture dish following apoptotic stimuli, and lysates of apoptotic and control cells were subjected to immunoblot analysis. The protein levels of p53 and most p53 targets, including Bax, p21, and GADD45, increased in apoptotic Rat-1 cells (Fig. 1A). In contrast, the MDM2 protein decreased in these apoptotic cells to barely detectable levels (Fig. 1B).


Fig. 1. Degradation of MDM2 in apoptotic cells. Rat-1 fibroblasts (A and B) or PC12 rat pheochromocytoma cells (C) were cultured in serum-free medium (serum deprivation) for 16 h to induce apoptosis or left in growth medium (control). Alternatively, apoptosis was induced by treatment of cells in growth medium with PI 3-kinase inhibitors, 0.5 µM wortmannin or 50 µM LY294002, for 6 and 16 h, respectively (22, 23). All cells from control cultures and detached apoptotic cells following serum deprivation or treatment with PI 3-kinase inhibitors were collected, and cell lysates containing 50 µg of protein were processed for immunoblot analysis of the indicated proteins. The results are representative of at least five similar experiments.
[View Larger Version of this Image (39K GIF file)]

Similar disappearance of MDM2 was observed in apoptotic Rat-1 cells upon treatment with PI 3-kinase inhibitors (data not shown) and in apoptotic PC12 cells after either growth factor deprivation or treatment with PI 3-kinase inhibitors (Fig. 1C). In contrast, as in Rat-1 cells, apoptotic PC12 cells contained increased levels of p53, Bax, p21, and GADD45 proteins (not shown). It thus appeared that p53 and proteins encoded by most p53 target genes were induced in apoptotic Rat-1 and PC12 cells, whereas the levels of MDM2 were strikingly reduced.

To account for the loss of MDM2 in apoptotic cells, we considered the possibility that MDM2 was cleaved by apoptotic proteases. Proteases of the CPP32 subfamily were activated in both apoptotic Rat-1 and PC12 cells, as indicated by cleavage of the CPP32 substrate PARP (Fig. 2A). CPP32-like proteases recognize the consensus sequence DXXD, with cleavage after the second D (10). Consistent with the possibility that MDM2 is a substrate for these proteases, six potential DXXD cleavage sites are present in mouse MDM2, and four of these sites are conserved in human and hamster (Fig. 2B). Cleavage at these multiple sites would degrade MDM2 into small fragments, consistent with the lack of detectable MDM2 in immunoblots with antibody against amino acids 154-167 (Fig. 1B).


Fig. 2. A, cleavage of PARP in apoptotic cells. Cell lysates from Fig. 1 were used for immunoblot analysis. Intact PARP (116 kDa) and the cleaved fragment (85 kDa) are indicated by arrows. The results are representative of at least three similar experiments. B, putative cleavage sites of CPP32-like proteases in MDM2. The potential DXXD recognition sites for CPP32-like proteases in the mouse MDM2 sequence (17) are indicated with bold underlined letters. These sites are conserved in mouse, hamster (GenBankTM accession number V10982[GenBank]), and human (17, 24), except for Asp131, which is replaced with Glu in hamster, and Asp224, which is replaced with Ala in human.
[View Larger Version of this Image (36K GIF file)]

Cleavage of MDM2 with Apoptotic Cytosols

To investigate the possible cleavage of MDM2 by apoptotic proteases, we used an in vitro cleavage assay (20) in which [35S]methionine-labeled MDM2 prepared by in vitro translation was added to cytosols of apoptotic cells. Cytosols were prepared from U937 cells, which provide an efficient source of active apoptotic proteases (19). As previously reported (24, 25), in vitro translated MDM2 migrated at 90 kDa, even though the size predicted from the amino acid sequence is ~55 kDa. Incubation of MDM2 with cytosol from etoposide-treated apoptotic U937 cells resulted in a loss of intact MDM2 protein, whereas control cytosol from untreated cells had no effect (Fig. 3A, first three lanes). Moreover, with apoptotic cytosol we observed a concomitant appearance of two prominent MDM2 fragments. The sum of the apparent molecular masses of the two fragments (60 and 30 kDa) was approximately equal to the apparent molecular mass of intact MDM2 (90 kDa), indicating that a single site in MDM2 was most sensitive to cleavage by apoptotic proteases.


Fig. 3. In vitro cleavage of MDM2 by apoptotic cytosol. A, in vitro translated 35S-MDM2 was incubated without cytosol or with 5 µg of cytosolic extracts from control or apoptotic U937 cultures. In lanes 4 and 5, the indicated peptide inhibitors (0.1 µM) were added to the reactions. MDM2 and its cleavage products were separated on SDS-polyacrylamide gel and analyzed by a PhosphorImager (Molecular Dynamics). The apparent molecular masses of intact MDM2 (90 kDa) and its fragments (30 and 60 kDa) are marked by arrows. The results are representative of at least five similar experiments. B, cytosolic extracts from apoptotic U937 cells were subjected to two sequential immunoprecipitations with either anti-CPP32 or the nonrelated anti-p21 antibody as control. In vitro translated 35S-MDM2 was incubated in the presence of 5 or 10 µg of control (+CPP32) and immunodepleted (-CPP32) cytosolic extracts, subjected to polyacrylamide gel electrophoresis, and analyzed by a PhosphorImager. Data are presented as the amount of intact MDM2 remaining after indicated times of incubation. The results are representative of two similar experiments.
[View Larger Version of this Image (24K GIF file)]

To identify the apoptotic proteases responsible for cleavage of MDM2, we added ICE protease inhibitors. DEVD-CHO, which potently inhibits both the CPP32-like and the ICE-like subfamilies (26),3 abolished the MDM2 cleavage activity of apoptotic cytosol (Fig. 3A, fifth lane). In contrast, YVAD-CHO, which is a selective inhibitor of the ICE-like subfamily (26), did not affect MDM2 cleavage (Fig. 3A, fourth lane). Thus, MDM2 cleavage in apoptotic cytosol is catalyzed by CPP32-like as opposed to ICE-like proteases.

To further investigate the role of CPP32 in MDM2 cleavage, we immunodepleted apoptotic cytosol with anti-CPP32 antibody. This removed the majority (at least 90%) of CPP32 from the cytosol as assessed by immunoblotting and decreased MDM2 cleavage activity by approximately 50% (Fig. 3B). It thus appears that CPP32 is a major source of MDM2 cleavage in apoptotic cytosol. However, cleavage of MDM2 may also be catalyzed by other members of the CPP32 subfamily.

Cleavage of MDM2 by Purified Proteases

To directly analyze the ability of CPP32 to cleave MDM2, we tested the activity of CPP32 purified from an E. coli expression system, in which CPP32 is activated as a result of autocatalytic cleavage (21). Incubation with purified CPP32 resulted in the initial cleavage of MDM2 to two fragments of the same size as those produced by apoptotic cytosol (Fig. 4A). Incubation with increased amounts of CPP32 (or incubation for longer times; data not shown) resulted in the disappearance of the larger fragment, whereas the amount of the smaller fragment remained fairly constant. These results suggest that CPP32 cleaves MDM2 preferentially at a single site, giving rise to two fragments. The sizes of these fragments suggest that this initial cleavage site corresponds to the consensus site located nearest to either the amino or carboxyl terminus of MDM2 (DLKD or DVPD), rather than to one of the potential cleavage sites in the middle of the MDM2 sequence (Fig. 2). The larger fragment then appears to be degraded as a result of cleavage at the multiple additional DXXD sites present in MDM2. This degradation of the larger fragment in vitro is consistent with the absence of any detectable fragment of MDM2 in apoptotic cell lysates (Fig. 1B).


Fig. 4. Cleavage of MDM2 by purified proteases. A, the indicated amounts of affinity-purified CPP32 were incubated with 35S-MDM2 for 1 h at 30 °C, and MDM2 cleavage was analyzed by polyacrylamide gel electrophoresis. B, 0.1 units of the indicated enzymes were incubated with 35S-MDM2 as above. ICE and Mch3 were bacterial lysates, Mch2 was an affinity-purified enzyme, and CPP32 was used in both forms. The results are representative of at least three similar experiments.
[View Larger Version of this Image (30K GIF file)]

We then tested MDM2 cleavage by other members of the ICE protease family. ICE did not cleave MDM2 in vitro (Fig. 4B, ICE lane). In contrast, two other members of the CPP32 subfamily, Mch2 (caspase-6) and Mch3 (caspase-7) (7-9), were able to cleave MDM2, producing fragments the same size as those produced by apoptotic cytosol or purified CPP32 (Fig. 4B, Mch3 and Mch2 lanes). In addition, Mch2 yielded a third major cleavage product with apparent molecular mass <30 kDa. However, the cleavage of MDM2 by either Mch2 or Mch3 was significantly less efficient than cleavage by CPP32.

These results suggest that there is a limited specificity of MDM2 cleavage for CPP32, and other CPP32 subfamily members (Mch2 and Mch3) also contribute to the cleavage activity. This cleavage of MDM2 by other CPP32-like proteases probably accounts for the remaining activity of apoptotic cytosol following immunodepletion of CPP32 (Fig. 3B).

Cleavage of MDM2 Can Be Prevented by Mutation of Aspartate 359

Among the potential cleavage sites in MDM2, the conserved sequence between amino acids 356-359 (DVPD) appeared to be the most likely primary recognition site for CPP32, with cleavage after aspartate 359. This site is almost identical to those in the 70-kDa component of the U1 ribonucleoprotein (DGPD) (10) and in the sterol-regulatory element binding protein 2 (DEPD) (12). Moreover, cleavage at this site would yield two fragments similar in size to those identified in vitro. We therefore introduced a mutation into MDM2, replacing aspartate 359 with glutamic acid (D359E). The mutated MDM2 was resistant to cleavage either by apoptotic cytosol or by purified CPP32 (Fig. 5A), identifying aspartate 359 as the primary site of CPP32 cleavage.


Fig. 5. Mutation of aspartate 359 prevents MDM2 cleavage. A, WT and the D359E mutant MDM2 proteins were tested for in vitro cleavage as described in Figs. 3 and 4, using either 5 µg of cytosolic extracts or 0.1 unit of purified recombinant enzymes. The results are representative of at least five similar experiments. B, HA-tagged WT and D359E mdm2 were transiently transfected into COS-7 cells. Cells were incubated in DMEM supplemented with 10% calf serum for 24 h and then incubated for an additional 2 days, either in serum-free medium (serum deprivation +) or in medium containing 10% calf serum (serum deprivation -). Both detached and attached cells were harvested, and 20 µg of cell lysates were electrophoresed in a SDS-polyacrylamide gel and subjected to immunoblot analysis with an anti-HA monoclonal primary antibody. The results are representative of three similar experiments.
[View Larger Version of this Image (34K GIF file)]

To determine whether aspartate 359 was also a primary site of MDM2 cleavage in vivo, COS-7 cells were transiently transfected with amino-terminal HA-tagged MDM2 expression plasmids. Transfected cells were deprived of growth factors, and the tagged proteins were detected by immunoblotting with anti-HA antibody. With HA-tagged wild type MDM2, a 60-kDa HA-tagged fragment was observed (Fig. 5B, HA-mdm2 lanes). The formation of this fragment was increased following growth factor deprivation, although some cleavage was seen in control cells, probably reflecting apoptosis resulting from toxicity of the lipofectamine transfection procedure. In contrast, no cleavage was detected in cells transfected with HA-tagged D359E mutant MDM2 (Fig. 5B, HA-D359E-mdm2 lanes), indicating that this mutation protects MDM2 from cleavage in vivo.

These results identify the oncoprotein MDM2 as a novel substrate for the CPP32-subfamily of apoptotic proteases. As an inhibitor of p53, MDM2 plays a direct role in the regulation of apoptosis. The biological significance of MDM2 as a negative regulator of p53 is illustrated by the amplification and overexpression of MDM2 in a variety of tumors, particularly sarcomas, containing normal p53 genes (24). Overexpression of MDM2 in transfected cells also inhibits both p53-induced apoptosis and cell cycle arrest (27, 28). It thus appears that induction of MDM2 by p53 forms a negative feedback loop that is critical to regulation of the growth suppressive and apoptotic activities of p53. Our results indicate that cleavage of MDM2 by CPP32-like proteases breaks this feedback loop in apoptotic cells, resulting in deregulation of p53 and potentially contributing directly to the process of apoptotic cell death.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant RO1 CA18689.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Div. of Molecular Genetics, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Tel.: 617-375-8225; Fax: 617-375-8237; E-mail: geoffrey_cooper{at}dfci.harvard.edu.
1   The abbreviations used are: ICE, interleukin 1-beta convertase; DMEM, Dulbecco's modified Eagle's medium; WT, wild type; HA, hemagglutinin; PARP, poly(ADP-ribose) polymerase; PIPES, 1,4-piperazinediethanesulfonic acid; AMC, aminomethylcoumarine; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; PI, phosphatidylinositol.
2   R. Yao, P. Erhardt, and G. M. Cooper, unpublished observations.
3   K. J. Tomaselli, unpublished observations.

ACKNOWLEDGEMENTS

We thank J. Krebs, B. Smidt, and L. Kodandapani for caspase expression and purification.


REFERENCES

  1. Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. (1993) Science 262, 695-700 [Medline] [Order article via Infotrieve]
  2. Thompson, C. B. (1995) Science 267, 1456-1462 [Medline] [Order article via Infotrieve]
  3. White, E. (1996) Genes & Dev. 10, 1-15 [CrossRef][Medline] [Order article via Infotrieve]
  4. Martin, S. J., and Green, D. R. (1995) Cell 82, 349-352 [Medline] [Order article via Infotrieve]
  5. Vaux, D. L., and Strasser, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2239-2244 [Abstract/Free Full Text]
  6. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. (1993) Cell 75, 641-652 [Medline] [Order article via Infotrieve]
  7. Chinnaiyan, A. M., and Dixit, V. M. (1996) Curr. Biol. 6, 555-562 [Medline] [Order article via Infotrieve]
  8. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996) Cell 87, 171 [Medline] [Order article via Infotrieve]
  9. Henkart, P. A. (1996) Immunity 4, 195-201 [Medline] [Order article via Infotrieve]
  10. Casciola-Rosen, L., Nicholson, D. W., Chong, T., Rowan, K. R., Thornberry, N. A., Miller, D. K., and Rosen, A. (1996) J Exp. Med. 183, 1947-1951 [Medline] [Order article via Infotrieve]
  11. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347 [CrossRef][Medline] [Order article via Infotrieve]
  12. Wang, X., Zelenski, N. G., Yang, J., Sakai, J., Brown, M. S., and Goldstein, J. L. (1996) EMBO J. 15, 1012-1020 [Abstract]
  13. Rao, L., Perez, D., and White, E. (1996) J. Cell Biol. 135, 1441-1455 [Abstract]
  14. Levine, A. (1993) Annu. Rev. Biochem. 62, 623-651 [CrossRef][Medline] [Order article via Infotrieve]
  15. Ko, L. J., and Prives, C. (1996) Genes & Dev. 10, 1054-1072 [CrossRef][Medline] [Order article via Infotrieve]
  16. Gottlieb, M. T., and Oren, M. (1996) Biochim. Biophys. Acta 1287, 77-102 [CrossRef][Medline] [Order article via Infotrieve]
  17. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. (1991) EMBO J. 10, 1565-1569 [Abstract]
  18. Sells, M. A., and Chernoff, J. (1995) Gene (Amst.) 152, 187-189 [CrossRef][Medline] [Order article via Infotrieve]
  19. Erhardt, P., and Cooper, G. M. (1996) J. Biol. Chem. 271, 17601-17604 [Abstract/Free Full Text]
  20. Enari, M., Hase, A., and Nagata, S. (1995) EMBO J. 14, 5201-5208 [Abstract]
  21. Armstrong, R. C., Aja, T., Xiang, J., Gaur, S., Krebs, J. F., Hoang, H., Bai, X., Korsmeyer, S. J., Karanewsky, D. S., Fritz, L. C., and Tomaselli, K. J. (1996) J. Biol. Chem. 271, 16850-16855 [Abstract/Free Full Text]
  22. Yao, R., and Cooper, G. M. (1995) Science 267, 2003-2006 [Medline] [Order article via Infotrieve]
  23. Yao, R., and Cooper, G. M. (1996) Oncogene 13, 343-351 [Medline] [Order article via Infotrieve]
  24. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. (1992) Nature 358, 80-83 [CrossRef][Medline] [Order article via Infotrieve]
  25. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) Cell 69, 1127-1132
  26. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., and Miller, D. K. (1995) Nature 376, 37-43 [CrossRef][Medline] [Order article via Infotrieve]
  27. Haupt, Y., Barak, Y., and Oren, M. (1996) EMBO J. 15, 1596-1606 [Abstract]
  28. Chen, J., Wu, X., Lin, J., and Levine, A. J. (1996) Mol. Cell. Biol. 16, 2445-2452 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.